Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Developments study identified that conolidine interacts Along with the atypical chemokine receptor ACKR3… Read More